April 24, 2020The Food and Drug Administration (FDA) has cleared the way for accelerated public release of several validated digital devices for treating psychiatric disorders during the pandemic.1 Endeavor™ (AKL-TO1), from Akili Interactive, is one of several low-risk, clinically validated therapeutics that is now being made available, though without formal FDA clearance, for a limited time during the crisis.2 Akili has been working with the FDA on approval of Endeavor™ as a prescription treatment for use in pediatric ADHD.
The treatment has been evaluated in more than 600 children with ADHD across five clinical studies.Endeavor™ is based on a game called NeuroRacer, which was designed by neuroscientist Adam Gazzaley, M.D., Ph.D., Akili’s
Read more on additudemag.com